Jump to main content.

Glycidaldehyde Quickview (CASRN 765-34-4)

Health assessment information on a chemical substance is included in IRIS only after a comprehensive review of toxicity data by U.S. EPA health scientists from several Program Offices, Regional Offices, and the Office of Research and Development.

Disclaimer: This QuickView represents a snapshot of key information. We suggest that you read the IRIS Summary to put this information into complete context.

For definitions of terms in the IRIS Web site, refer to the IRIS Glossary.

Status of Data for Glycidaldehyde

File First On-Line: 08/22/1988; Last Significant Revision: 08/01/1991

Category (section)
Last Revised
Oral RfD Assessment Yes 08/22/1988
Inhalation RfC Assessment No
Carcinogenicity Assessment Yes 08/01/1991
  • 765-34-4
  • Epihydrinaldehyde
  • Epihydrine aldehyde
  • 2,3-Epoxypropanal
  • 2,3-Epoxy-1-propanal
  • 2,3-Epoxypropionaldehyde
  • Formyloxiran
  • Glycidal
  • Glycidaldehyde
  • Glycidyaldehyde
  • Glycidylaldehyde
  • more...
Glycidaldehyde Source Documents
Chronic Health Hazard Assessments for Noncarcinogenic Effects

Reference Dose for Chronic Oral Exposure (RfD)

Critical Effect
Point of Departure*
Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects NOAEL : 1.09 mg/kg-day 3000 4 x10-4 mg/kg-day

* The Point of Departure listed serves as a basis from which the Oral RfD was derived. See Discussion of Conversion Factors and Assumptions for more details.

Top of page

Reference Concentration for Chronic Inhalation Exposure (RfC)

Not Assessed under the IRIS Program.

Top of page

Carcinogenicity Assessment for Lifetime Exposure
  • Weight-of-Evidence Characterization
    • B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals)
  • Weight-of-Evidence Narrative:
    • Based on no human data and an increased incidence of malignant tumors in rats and mice following subcutaneous injection of glycidaldehyde and of skin carcinomas following dermal application to mice. Glycidaldehyde shows mutagenic activity in many assay systems and is known to be highly reactive because of the epoxide and the aldehyde groups. A number of structurally related epoxide compounds are also carcinogenic in experimental animals, including the analogues glycidol and propylene oxide.
    • This may be a synopsis of the full weight-of-evidence narrative. See IRIS Summary.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure

  • Not Assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure

  • Not Assessed under the IRIS Program.

Top of page

Recent Additions | Advanced Search | IRIS Home | Environmental Assessment | Research

Local Navigation

Jump to main content.